Olpasiran
amgen
['arrowhead', 'amgen']
today at #aha22, our partners released new phase 2 data &amp; simultaneously published an article in around the potential of trim-enabled #rnai candidate olpasiran to reduce lipoprotein(a) levels. read here: 
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.